Profiel
Harvey N.
Masonson held several positions in the pharmaceutical industry, including Assistant Director-Clinical Safety at Bristol Myers Squibb Co., Director-Clinical Research at Sanofi-Synthelabo, Inc., Vice President-Clinical Development & Drug Safety at (OSI).
Eyetech, and Senior Vice President-Clinical Development at IVERIC bio, Inc. He also served as Vice President-Clinical Development at Gensight Biologics SA from 2018 to 2019.
Masonson earned a doctorate degree from the Icahn School of Medicine at Mount Sinai.
Eerdere bekende functies van Harvey N. Masonson
| Bedrijven | Functie | Einde |
|---|---|---|
| GENSIGHT BIOLOGICS S.A. | Chief Tech/Sci/R&D Officer | 01-01-2019 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
(OSI) Eyetech
 (OSI) Eyetech Medical SpecialtiesHealth Technology OSI Eyetech provides medical services. It is specializee in the development and commercialization of therapeutics to treat diseases of the eye. The company is headquartered in New York City, NY. | Corporate Officer/Principal | - |
| Sanofi-Synthelabo, Inc. | Chief Tech/Sci/R&D Officer | - |
| IVERIC BIO, INC. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Harvey N. Masonson
| Icahn School of Medicine at Mount Sinai | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GENSIGHT BIOLOGICS S.A. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
(OSI) Eyetech
(OSI) Eyetech Medical SpecialtiesHealth Technology OSI Eyetech provides medical services. It is specializee in the development and commercialization of therapeutics to treat diseases of the eye. The company is headquartered in New York City, NY. | Health Technology |
IVERIC bio, Inc.
 IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
| Sanofi-Synthelabo, Inc. | Health Technology |
